IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
Provided By GlobeNewswire
Last update: Aug 12, 2024
NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer, today announced updated positive clinical data from both of the Company’s Phase 1 investigator-sponsored trials of INB-100 for hematological malignancies and INB-200 for GBM. The Company has also completed a Type B meeting with the FDA and received guidance on the registrational path to advance INB-100 for the treatment of AML.
Read more at globenewswire.com0.2715
-0.01 (-5.07%)
Find more stocks in the Stock Screener
INAB Latest News and Analysis
9 days ago - ChartmillThe trading volume of these stocks is deviating from the norm in today's session.Which stocks have an unusual volume on Thursday?
10 days ago - ChartmillUnusual volume stocks in Wednesday's sessionDiscover the stocks with unexpected trading volume in today's session on the US markets.
11 days ago - ChartmillWhich stocks are moving after the closing bell on Tuesday?Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
11 days ago - ChartmillThese stocks are making the most noise in today's session.These stocks are making the most noise in today's session. Stay tuned for the latest updates!
11 days ago - ChartmillTuesday's session: gap up and gap down stocksLet's have a look at the gap up and gap down stocks in today's session.
11 days ago - ChartmillWhich stocks are moving before the opening bell on Tuesday?As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
